{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:15:31Z","timestamp":1788192931579,"version":"build-2803163510"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Use of cannabis edibles is increasing, yet little is known about the impact of edibles on driving, which is particularly important in the context of per se thresholds (commonly 2 or 5 ng\/mL) used to enforce cannabis-impaired driving laws.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine whether driving simulator performance is dose-dependently impaired by commercially available edible cannabis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This randomized, double-blind, placebo-controlled, crossover clinical trial was completed at a single-site tertiary care academic hospital in Toronto, Ontario, Canada, between September 2024 and April 2025. Participants were healthy adults aged 19 to 45 years endorsing at least weekly cannabis use and monthly use of cannabis edibles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Edible (oral) delta-9-tetrahydrocannabinol (THC) was administered to all participants in soft-chew gummies, 0 or 2 mg each, to achieve doses of 0, 2, 10, and 20 mg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Standard deviation of lateral position (SDLP) in simulated driving scenarios at 2 and 5 hours after THC exposure was the primary outcome (reported as difference in means [95% CIs]) assessed in the intention-to-treat population. Secondary outcomes included driving simulator standard deviation of speed (SDS) and reaction time (RT), self-reported driving willingness and perceived ability, and whole-blood THC and metabolite levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 85 potential participants, 52 were enrolled as eligible, 10 withdrew before receiving a dose of THC, and 2 were removed from the analysis. Thus, 40 participants (20 [50.0%] female and 20 [50.0%] male) were included in the analysis (mean [SD] age, 30.4 [6.9] years). Relative to placebo, SDLP was significantly increased at 20 mg (3.3 [95% CI, 2.4 to 4.3] cm;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) and 10 mg (2.0 [95% CI, 1.0 to 2.9] cm;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001), but not 2 mg (0.7 [95% CI, \u22120.3 to 1.6] cm;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.16). The secondary driving measures RT and SDS were also negatively influenced by THC exposure. For example, compared with placebo, RT was significantly higher at 20 mg (difference in means, 0.034 [95% CI, 0.018 to 0.050] s;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) and SDS was significantly increased at 20 mg (difference in means, 0.469 [95% CI, 0.154 to 0.784] km\/h;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.004). Self-reported driving measures were dose-dependently decreased by THC dose. For example, compared with placebo, willingness to drive was significantly decreased at 20 mg (difference in means, \u22122.113 [95% CI, 1.166-1.821];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001), as was participant-perceived driving ability (difference in means, \u22121.694 [95% CI, 1.422-1.966]\n                      <jats:italic>; P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). Whole-blood THC concentrations (peaks of 3.4 and 1.6 ng\/mL at 20 and 10 mg, respectively) were near or below common per se thresholds for driving.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this crossover randomized clinical trial of driving performance after exposure to THC edibles, THC dose-dependently impaired simulated driving performance at blood THC concentrations below per se thresholds commonly used for roadside enforcement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT06595576?term=NCT06595576&amp;amp;amp;viewType=Card&amp;amp;amp;rank=1\">NCT06595576<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.31306","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:30:24Z","timestamp":1788190224000},"page":"e2631306","source":"Crossref","is-referenced-by-count":0,"title":["Dose-Dependent Effects of Cannabis Edibles on Simulated Driving Performance"],"prefix":"10.1001","volume":"9","author":[{"given":"Bernard","family":"Le Foll","sequence":"first","affiliation":[{"name":"Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Campbell Family Mental Health Research Institute Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Matheson","sequence":"additional","affiliation":[{"name":"Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Antwi","sequence":"additional","affiliation":[{"name":"Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Wright","sequence":"additional","affiliation":[{"name":"Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Zaweel","sequence":"additional","affiliation":[{"name":"Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer S. M.","family":"Hasan","sequence":"additional","affiliation":[{"name":"Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kloiber","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Campbell Family Mental Health Research Institute Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada"},{"name":"Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed N.","family":"Hassan","sequence":"additional","affiliation":[{"name":"Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Campbell Family Mental Health Research Institute Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada"},{"name":"Addiction Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Sproule","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada"},{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada"},{"name":"Pharmacy, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Wickens","sequence":"additional","affiliation":[{"name":"Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Campbell Family Mental Health Research Institute Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Di Ciano","sequence":"additional","affiliation":[{"name":"Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Campbell Family Mental Health Research Institute Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Brands","sequence":"additional","affiliation":[{"name":"Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Controlled Substances and Cannabis Branch, Health Canada, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"zoi260863r1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e536","article-title":"Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis.","volume":"344","author":"Asbridge","year":"2012","journal-title":"BMJ"},{"issue":"8","key":"zoi260863r2","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/add.13347","article-title":"The effects of cannabis intoxication on motor vehicle collision revisited and revised.","volume":"111","author":"Rogeberg","year":"2016","journal-title":"Addiction"},{"key":"zoi260863r3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.aap.2012.06.017","article-title":"Risk of road accident associated with the use of drugs: a systematic review and meta-analysis of evidence from epidemiological studies.","volume":"60","author":"Elvik","year":"2013","journal-title":"Accid Anal Prev"},{"issue":"2","key":"zoi260863r4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/15389588.2015.1052421","article-title":"Delays in DUI blood testing: impact on cannabis DUI assessments.","volume":"17","author":"Wood","year":"2016","journal-title":"Traffic Inj Prev"},{"issue":"8","key":"zoi260863r5","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics.","volume":"4","author":"Huestis","year":"2007","journal-title":"Chem Biodivers"},{"issue":"3","key":"zoi260863r6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1373\/clinchem.2012.194381","article-title":"Cannabis effects on driving skills.","volume":"59","author":"Hartman","year":"2013","journal-title":"Clin Chem"},{"key":"zoi260863r7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.copsyc.2019.04.002","article-title":"Changing landscape of cannabis: novel products, formulations, and methods of administration.","volume":"30","author":"Spindle","year":"2019","journal-title":"Curr Opin Psychol"},{"key":"zoi260863r8","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1111330","article-title":"On offer to Ontario consumers three years after legalization: a profile of cannabis products, cannabinoid content, plant type, and prices.","volume":"14","author":"Tassone","year":"2023","journal-title":"Front Psychiatry"},{"key":"zoi260863r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2026.108508","article-title":"Increasing use of cannabis edibles in response to recreational cannabis legalization in the United States.","volume":"204","author":"Hawkins","year":"2026","journal-title":"Prev Med"},{"issue":"1","key":"zoi260863r11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s42238-024-00234-y","article-title":"The effect of cannabis edibles on driving and blood THC.","volume":"6","author":"Zhao","year":"2024","journal-title":"J Cannabis Res"},{"issue":"11\/12","key":"zoi260863r12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15389588.2025.2574271","article-title":"Edible cannabis use on simulated driving performance.","volume":"2025","author":"Won","year":"2025","journal-title":"Traffic Inj Prev"},{"issue":"14","key":"zoi260863r13","doi-asserted-by":"publisher","first-page":"E481","DOI":"10.1503\/cmaj.191032","article-title":"Impaired driving and legalization of recreational cannabis.","volume":"193","author":"Windle","year":"2021","journal-title":"CMAJ"},{"issue":"12","key":"zoi260863r14","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1373\/clinchem.2016.263475","article-title":"Free and glucuronide whole blood cannabinoids\u2019 pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake.","volume":"62","author":"Newmeyer","year":"2016","journal-title":"Clin Chem"},{"issue":"1","key":"zoi260863r15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.18433\/J3GP53","article-title":"Understanding the hysteresis loop conundrum in pharmacokinetic\/pharmacodynamic relationships.","volume":"17","author":"Louizos","year":"2014","journal-title":"J Pharm Pharm Sci"},{"issue":"4","key":"zoi260863r16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.tips.2017.01.006","article-title":"Drugs and driving research in medicinal drug development.","volume":"38","author":"Ramaekers","year":"2017","journal-title":"Trends Pharmacol Sci"},{"issue":"21","key":"zoi260863r17","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1001\/jama.2020.21218","article-title":"Effect of cannabidiol and ?9-tetrahydrocannabinol on driving performance: a randomized clinical trial.","volume":"324","author":"Arkell","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"zoi260863r18","doi-asserted-by":"publisher","first-page":"12961","DOI":"10.1038\/s41598-026-43045-2","article-title":"Potency-related effects of smoked cannabis on simulated driving performance: a randomized, controlled crossover trial.","volume":"16","author":"Brands","year":"2026","journal-title":"Sci Rep"},{"issue":"22","key":"zoi260863r19","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2025.4347","article-title":"CONSORT 2025 Statement: updated guideline for reporting randomized trials.","volume":"333","author":"Hopewell","year":"2025","journal-title":"JAMA"},{"issue":"2","key":"zoi260863r20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"zoi260863r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107641","article-title":"Acute and residual effects of smoked cannabis: impact on driving speed and lateral control, heart rate, and self-reported drug effects.","volume":"205","author":"Brands","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"zoi260863r22","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00213-021-05773-3","article-title":"Combined effect of alcohol and cannabis on simulated driving.","volume":"239","author":"Fares","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"zoi260863r23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2147\/IJGM.S19639","article-title":"Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP).","volume":"4","author":"Verster","year":"2011","journal-title":"Int J Gen Med"},{"issue":"7","key":"zoi260863r24","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/02698811211021583","article-title":"Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis.","volume":"35","author":"Spindle","year":"2021","journal-title":"J Psychopharmacol"},{"issue":"2","key":"zoi260863r25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/15389588.2020.1851685","article-title":"The failings of per se limits to detect cannabis-induced driving impairment: results from a simulated driving study.","volume":"22","author":"Arkell","year":"2021","journal-title":"Traffic Inj Prev"},{"key":"zoi260863r26","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.641549","article-title":"Cannabis, impaired driving, and road safety: an overview of key questions and issues.","volume":"12","author":"Brands","year":"2021","journal-title":"Front Psychiatry"},{"key":"zoi260863r10","unstructured":"Canadian cannabis survey 2024: summary. Government of Canada: Health Canada. Accessed June 17, 2025. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-medication\/cannabis\/research-data\/canadian-cannabis-survey-2024-summary.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2853465\/le_foll_2026_oi_260863_1787587636.06784.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:30:25Z","timestamp":1788190225000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2853465"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.31306","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}